Evidence map›Paper›PMID 36379534›Full record

ArticleSaudi medical journal2022

Antibacterial and anti-biofilm activity of plumbagin against multi-drug resistant clinical bacterial isolates.

Mohammad A Alfhili, Irfan Ahmad, Yasser Alraey, Abdulaziz Alangari, Taha Alqahtani, Ayed A Dera

Open access · diamondFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Antiparasitic Activity ofPharmaceutics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mohammad A AlfhiliFrom the Chair of Medical and Molecular Genetics Research (Alfhili), Department of Clinical Laboratory Sciences, from the Department of Clinical Laboratory Sciences (Alangari), College of Applied Medical Sciences, King Saud University, Riyadh; from the Department of Clinical Laboratory Sciences (Ahmad, Alraey, Dera), College of Applied Medical Sciences, and from the Department of Pharmacology (Alqahtani), College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia.
Irfan AhmadFrom the Chair of Medical and Molecular Genetics Research (Alfhili), Department of Clinical Laboratory Sciences, from the Department of Clinical Laboratory Sciences (Alangari), College of Applied Medical Sciences, King Saud University, Riyadh; from the Department of Clinical Laboratory Sciences (Ahmad, Alraey, Dera), College of Applied Medical Sciences, and from the Department of Pharmacology (Alqahtani), College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia.
Yasser AlraeyFrom the Chair of Medical and Molecular Genetics Research (Alfhili), Department of Clinical Laboratory Sciences, from the Department of Clinical Laboratory Sciences (Alangari), College of Applied Medical Sciences, King Saud University, Riyadh; from the Department of Clinical Laboratory Sciences (Ahmad, Alraey, Dera), College of Applied Medical Sciences, and from the Department of Pharmacology (Alqahtani), College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia.
Abdulaziz AlangariFrom the Chair of Medical and Molecular Genetics Research (Alfhili), Department of Clinical Laboratory Sciences, from the Department of Clinical Laboratory Sciences (Alangari), College of Applied Medical Sciences, King Saud University, Riyadh; from the Department of Clinical Laboratory Sciences (Ahmad, Alraey, Dera), College of Applied Medical Sciences, and from the Department of Pharmacology (Alqahtani), College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia.
Taha AlqahtaniFrom the Chair of Medical and Molecular Genetics Research (Alfhili), Department of Clinical Laboratory Sciences, from the Department of Clinical Laboratory Sciences (Alangari), College of Applied Medical Sciences, King Saud University, Riyadh; from the Department of Clinical Laboratory Sciences (Ahmad, Alraey, Dera), College of Applied Medical Sciences, and from the Department of Pharmacology (Alqahtani), College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia.
Ayed A DeraFrom the Chair of Medical and Molecular Genetics Research (Alfhili), Department of Clinical Laboratory Sciences, from the Department of Clinical Laboratory Sciences (Alangari), College of Applied Medical Sciences, King Saud University, Riyadh; from the Department of Clinical Laboratory Sciences (Ahmad, Alraey, Dera), College of Applied Medical Sciences, and from the Department of Pharmacology (Alqahtani), College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia.
King Khalid University · SAKing Saud University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the antibacterial activity of plumbagin (PGN) against multidrug resistance (MDR) clinical isolates.

methodsThis study was carried out at the Department of Clinical Lab Sciences, King Khalid University from October 6, 2021 to December 14, 2021. We investigated the antibacterial and anti-virulence activity of PGN against MDR Gram-negative (

resultsPlumbagin inhibited the growth of all tested isolates, with

conclusionPlumbagin is a stand-alone, broad spectrum antibacterial with promising potential against the rising threat of antimicrobial resistance.

Indexed as

Staphylococcal InfectionsStaphylococcus aureusAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialEscherichia coliHumansMicrobial Sensitivity TestsNaphthoquinonesAnti-Bacterial AgentsNaphthoquinonesplumbaginantibacterialbiofilmE. coliPlumbaginP. zeylanicaS. aureus

Identifiers

PMID36379534
PMCPMC10043915
OpenAlexW4309366884

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read32
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.